Sign in
Back
Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection
Journal article   Peer reviewed

Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection

Steven J. Moss, Michael Bobardt, Pieter Leyssen, Nigel Coates, Udayan Chatterji, Xie Dejian, Teresa Foster, Jinlun Liu, Mohammad Nur-e-Alam, Dipen Suthar, …
MedChemComm, Vol.3(8), pp.938-943
01/08/2012
DOI: https://doi.org/10.1039/c1md00227a

Abstract

Biochemistry & Molecular Biology Chemistry, Medicinal Life Sciences & Biomedicine Pharmacology & Pharmacy Science & Technology
Sangamides are amide derivatives of sanglifehrin A, a cyclophilin-binding polyketide natural product which is structurally distinct from cyclosporine A. Cyclosporine A is the starting point for the synthesis of cyclophilin inhibitors such as alisporivir, currently in development for the treatment of HCV infection. We report here initial results of the optimisation program which led to identification of the sangamides, compounds that exhibit significantly improved potential for the treatment of chronic HCV

Metrics

1 Record Views

Details